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Abstract
We recently demonstrated highly efficient antitumor immunity against dermal tumors of B16F10 murine melanoma with the use of den-
dritic cells (DCs) activated by replication-competent, as well as nontransmissible-type, recombinant Sendai viruses (rSeV), and proposed a
new concept, “immunostimulatory virotherapy,” for cancer immunotherapy. However, there has been little information on the efficacies of
this method: 1) inmore clinically relevant situations includingmetastatic diseases, 2) on other tumor types and other animal species, and 3)
on the related molecular/cellular mechanisms. In this study, therefore, we investigated the efficacy of vaccinating DCs activated by fusion
gene–deleted nontransmissible rSeV on a rat model of lung metastasis using a highly malignant subline of Dunning R-3327 prostate can-
cer, AT6.3. rSeV/dF–green fluorescent protein (GFP)–activated bone marrow–derived DCs (rSeV/dF-GFP-DC), consistent with results pre-
viously observed in murine DCs. Vaccination of rSeV/dF-GFP-DC was highly effective at preventing lung metastasis after intravenous
loading of R-3327 tumor cells, compared with the effects observed with immature DCs or lipopolysaccharide-activated DCs. Interest-
ingly, neither CTL activity nor DC trafficking showed any apparent difference among groups. Notably, rSeV/dF-DCs expressing a dominant-
negative mutant of retinoic acid–inducible gene I (RIG-I) (rSeV/dF-RIGIC-DC), an RNA helicase that recognizes the rSeV genome for inducing
type I interferons, largely lost the expression of proinflammatory cytokines without any impairment of antitumor activity. These results in-
dicate the essential role of RIG-I–independent signaling on antimetastatic effect induced by rSeV-activated DCs and may provide im-
portant insights to DC-based immunotherapy for advanced malignancies.
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Introduction
Prostate cancer is one of the most common malignancies among
Western populations, and its incidence in Japan is increasing. Since
the first report by Huggins and Hodges in 1941 [1], androgen abla-
tion has been the initial treatment of choice for men with metastatic
prostate cancer. However, these tumors eventually become androgen-
independent and progressed despite androgen ablation [2]. After all,
only 10% to 20% of patients with stage D2 prostate cancer are alive
5 years after diagnosis, by which time the options for treatment are
limited and most are palliative [2]. Conventional chemotherapy for
prostate cancer that is no longer responsive to androgen deprivation
was initially found to produce only marginal responses [3] but is now
being reevaluated with interest as new agents and better supportive
care become available [4,5]. Nevertheless, palliation remains the pri-
mary goal of current chemotherapy, and overall response rates are low
and associated with general toxicity [4]. Therefore, there has been a
serious demand for novel and well-tolerated strategies to treat pa-
tients with advanced and hormone-refractory prostate cancer.
Dendritic cells (DCs) have received much attention as a new thera-
peutic tool for cancer immunotherapy against advanced and hormone-
insensitive prostate cancers [6–8]. Although early clinical studies
successfully demonstrated cancer cell–specific immune responses in
tumor-bearing patients, the related clinical outcome of DC-based im-
munotherapy has been unsatisfactory [6–8], similar to findings ob-
served in other tumors [9]. These results, together with those of
clinical studies all over the world, indicate that a number of concerns
need to be examined, including practical issues (optimal numbers of
DCs and route, interval, and frequency of administration) as well as
DC qualities (subtype, phenotype, and activation status) [9].
To overcome these hurdles, we recently proposed a new concept,
“immunostimulatory virotherapy,” that provides efficient, DC-based
antitumor immunity against highly malignant B16F10 melanoma; this
immunity is induced by a new DC-activating modality, the replication-
competent [10] as well as nontransmissible [11] recombinant Sendai
viruses (rSeVs). SeV, a member of the family Paramyxoviridae, has a
nonsegmented negative-strand RNA genome and shows a broad spec-
trum of gene transfer [12–14], including DCs. rSeV can mediate
gene transfer and expression to a cytoplasmic location using cellular
tubulin [15], thereby avoiding possible malignant transformation due
to the genetic alteration of host cells; this is a safety advantage of
rSeV. Importantly, cytoplasmic replication and transcription of rSeV
would also be recognized by a DExD/H-box RNA helicase, retinoic
acid–inducible gene-I (RIG-I), leading cells to a variety of cellular
responses, including induction of type I interferons (IFNs) [16,17].
Such unique features of rSeV modulation of DC functions may
explain the efficient antitumor immunity of rSeV-DCs. However,
questions remain 1) whether rSeV-DC is also effective for clinically
more relevant situations, including lung metastasis, and 2) whether
the induction of antitumor immunity through rSeV-DC can be ex-
panded to other malignancies and animal species.
To answer these questions, we here investigated the antimetastatic
activity of DCs modified by nontransmissible rSeV lacking the F-gene
(rSeV/dF) [18]. Here, this rSeV/dF that has been used in the first
clinical gene therapy study in Japan was used to treat a rat model of
lung metastasis of a highly malignant subline of Dunning R-3327
(AT6.3) [19,20]. To examine the biologic functions of DCs modified
by rSeV/dF, we here used rSeV expressing a typical reporter gene, GFP.
This study successfully demonstrated that rSeV/dF-GFP-DC was rep-
resentatively effective for preventing pulmonary tumor metastasis in a
rat model of prostate cancer. Furthermore, we here show evidence that
the antitumor effect of rSeV/dF-DC was independent of the RIG-I–
related signal transduction pathway.
Materials and Methods
Animals and Tumor Cells
Male 6- to 8-week-old Copenhagen rats were obtained from the In-
stitute for Animal Reproduction (Tsukuba, Ibaraki, Japan). In some
experiments, male 8-week-old Wistar rats were also used as controls.
Rats were kept under specific pathogen-free and humane conditions
in the animal care facility of Chiba University’s Inohana campus.
The animal experiment was reviewed and approved by the Institu-
tional Animal Care and Use Committee and by the Biosafety Com-
mittee for Recombinant DNA experiments of Chiba University. These
experiments were also done in accordance with recommendations for
the proper care and use of laboratory animals and according to The
Law (No. 105) and Notification (No. 6) of the Japanese Government.
The AT6.3 clone, a highly metastatic, androgen-independent sub-
line from Dunning R-3327 rat prostate adenocarcinoma, served as a
model for experimental metastasis subsequent to intravascular tumor
inoculation. The development and characteristics of the AT6.3 sub-
line were described previously [20].
Monoclonal Antibodies
The following mouse antirat monoclonal antibodies (mAbs) were
used in this study. Biotin-conjugated OX35 (CD4), OX8 (CD8), and
OX17 (MHC class II) were purchased from BD Pharmingen (San
Diego, CA). Phycoerythrin (PE)-conjugated OX42 (CD11b/c), which
recognizes most DCs, monocytes/macrophages, and granulocytes in
part, was purchased fromGeneTex (SanAntonio,TX). Biotin-conjugated
B7-1 (CD80) and B7-2 (CD86) were from Cedarlane Laboratories
(Hornby, Ontario, Canada), and antirat pan-granulocyte (RK-4) were
from BMA (Augst, Switzerland). PE-conjugated OX62 (an integrin
on DCs) was from Serotec (Oxford, UK), and PE-conjugated antirat
ICAM-1 (intracellular adhesion molecule 1/CD54) was from R&D
Systems (Minneapolis, MN). Anti-CD45R (on B cells) was obtained
from e-Bioscience (San Diego, CA). Hamster antimouse CD40 (cross-
reacting with rat CD40) mAbs were purchased from Pharmingen.
Nontransmissible rSeVs (rSeV/dF)
Preparation and recovery of F-defective nontransmissible recombi-
nant SeVs (rSeV/dF-GFP, rSeV/dF-null, and rSeV/dF-RIGIC) were
performed as previously described [18]. Briefly, LLC-MK2 cells stably
transfected with pCALNdLw/F (the Cre/loxP-inducible F-gene ex-
pression plasmid) were maintained under G418 (400 μg/ml). F pro-
tein expression was induced by infecting an adenovirus-expressing Cre
recombinase (AxCANCre) at a multiplicity of infection (MOI) of 3.
Approximately 107 LLC-MK2 cells were infected with psoralen- and
long-wave UV-inactivated vaccinia virus expressing T7 RNA polymer-
ase (vTF7-3) at MOI = 2. The cells were then transfected with a plas-
mid mixture containing pSeV18+b(+)/dF, pGEM-NP, pGEM-P, and
pGEM-L by lipid-mediated gene transfer. The transfected cells were
maintained for 3 hours and incubated for 60 hours in minimum es-
sential medium containing ara-C. The cells were collected by centrifu-
gation, resuspended, and lysed by three cycles of freezing and thawing.
Subsequent genomic RNA nuclear protein complex transfection was
performed by cationic lipid into F-expressing LLC-MK2/F7 cells.
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Human RIG-IC complementary DNA, a dominant-negative form of
RIG-I that was subcloned to the vector template pSeV18+b(+)/dF, was
cloned by reverse transcription–polymerase chain reaction (RT-PCR)
as previously described [21].
Generation of Rat Bone Marrow–Derived DCs
DCs were obtained as previously described with additional negative
selection [22]. Briefly, bone marrow cells were harvested from femurs
and tibias. Red blood cells were lysed with VersaLyse lysing solution
(Beckman Coulter, Fullerton, CA). After washing, lineage antigen-
positive (CD45R, CD4, and CD8) cells and granulocytes were depleted
using the biotinylated primary antibodies and streptavidin-coated mag-
netic beads (Dynabeads MyOne Streptavidin; Invitrogen, Carlsbad, CA).
These cells were cultured under 20 ng/ml rat granulocyte/macrophage
colony-stimulating factor (GM-CSF; Peprotech, London, UK) and
10 ng/ml rat interleukin 4 (IL-4; Peprotech) in RPMI 1640 medium
with 10% fetal calf serum in six-well plates (5-10 × 104/5 ml per well).
On day 4, the culture medium was refreshed using medium supple-
mented with GM-CSF and IL-4 at the same concentrations. On
day 7, obtained immature DCs (iDCs) were collected and used for
subsequent experiments. For rSeV/dF–mediated transfection, DCs
were incubated with rSeV vectors at MOI 100 or as indicated. For
lipopolysaccharide (LPS)-mediated DC activation, DCs were cultured
in the same medium supplemented with 1 μg/ml LPS (Sigma-Aldrich
Japan, Tokyo, Japan). For tumor lysate preparation, AT6.3 cells were
processed by three rapid cycles of freezing and thawing. DCs were
pulsed with tumor lysate (DC number vs number of tumor cells
for lysate = 1:3) for 18 hours and then incubated with rSeV/dF or
LPS for 48 hours, as previously described [10]. For all injections,
materials were suspended in a 200-μl volume of phosphate-buffered
saline (PBS). When preparing rat bone marrow–derived DC (rBM-
DCs), we paid serious attention to maintaining an endotoxin-free
condition using endotoxin-free reagents throughout this study.
Flow Cytometric Analysis
rBM-DCs were analyzed by flow cytometry. The cells were incu-
bated with primary antibodies for 30 minutes at 4°C, and biotin-
ylated Abs were detected by subsequent staining with streptavidin-PE
or fluorescein isothiocyanate (FITC) (Pharmingen). Cells were ana-
lyzed using a FACS Calibur with the CellQuest software (D Bio-
sciences Japan, Tokyo, Japan). Data analysis was performed using
FlowJo 4.5 software (TREE STAR, Inc, San Carlos, CA). For surface
markers, DCs were replated in fresh medium (1 × 106/ml) and incu-
bated with SeV/dF without a foreign gene (MOI = 100) or 1 μg/ml
LPS for 48 hours. Biotin-conjugated antirat CD40, CD80, CD86,
MHC class II, and PE-conjugated OX62 (Pharmingen) mAbs were
used for each primary antibody, and biotinylated Abs were detected
by subsequent staining with streptavidin-FITC (Pharmingen). OX62
expression of rSeV/dF-GFP-DCs was observed in comparison with
that of LPS at different times after stimulation.
Real-time Quantitative RT-PCR
The cultured DCs were plated in fresh medium and were incubated
with rSeV/dF-GFP, rSeV/dF-RIGIC, or LPS for 48 hours. Total RNA
was extracted from each DC using a Micro-to-Midi Total RNA puri-
fication kit (Invitrogen) according to the manufacturer’s instructions.
After spectrophotometric quantification, reverse transcription was car-
ried out using random primers and SuperScript III reverse transcriptase
(Invitrogen). The expression of cytokines was examined by real-time
quantitative PCR using LightCycler (Roche Diagnostics, Mannheim,
Germany). The glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
gene served as an internal control. The PCR mixture consisted of
DNA Master SYBR Green I Mix (SYBR Green Two-Step qRT-PCR
Kit; Invitrogen), 1 μM of each primer, and complementary DNA. The
PCR processes were as follows: initial denaturation at 95°C for 1 min-
ute, followed by 45 cycles of denaturation at 95°C for 10 seconds, an-
nealing at 57°C for 10 seconds, and elongation at 72°C for 10 seconds.
To check the specificity of the amplified products, melting curve anal-
ysis was performed immediately after the completion of the PCR.
The melting protocol consisted of heating from 65 to 95°C at a rate
of 0.2°C per step and holding for 1 second at each step for data ac-
quisition. The primer sequences are listed on the Table W1.
ELISA
The DCs were plated in fresh medium and incubated with rSeV/
dF-GFP or LPS (1 ng/ml) for 48 hours. The culture media were har-
vested, and the concentration of rat tumor necrosis factor α (TNF-α)
was measured by a rat-specific ELISA kit (BioSource, Camarillo, CA)
according to the manufacturer’s instructions.
Vaccination
Rats were intravenously or intradermally vaccinated three times,
every other week, with appropriate numbers of immature, LPS-,
rSeV/dF-GFP-, or rSeV/dF-RIGIC-DCs pulsed with or without tu-
mor lysate. A day after the final vaccination, 5 × 105 AT6.3 cells sus-
pended in a 200-μl volume of PBS were inoculated intravenously.
Three weeks after injection, rats were killed, and their lung metastases
were counted by measuring lung weight and the number of metastatic
nodules on the lung surface. For immunologic assessment, a Cr51 re-
lease assay for cytolytic activity of CTL was performed.
Cr 51 Release Assay for CTL
Seven days after the third immunization, splenocytes were obtained,
and contaminated erythrocytes were depleted by VersaLyse lysing so-
lution. The effector splenocytes (4 × 106 cells/ml) were cocultured
with irradiated (100 Gy) AT6.3 cells (stimulator; 3 × 105 cells/ml)
for 5 days. Consequently, cells containing CTLs were harvested and
used as effector cells in a Cr51 release assay. Briefly, target tumor cells
(1 × 106) were labeled with 100 μCi of Na2
51CrO4 (Amersham Bio-
sciences, Piscataway, NJ) in 200 μl of medium for 90 minutes at 37°C.
The labeled target cells (1 × 104 cells per well) were incubated with
the effector cells for 4 hours at 37°C in 96-well plates in 200 μl
of T-cell medium at various E/T ratios. The plates were then centri-
fuged, and the radioactivity of the supernatants was counted using a
gamma counter. The maximum or spontaneous release was defined as
counts from samples incubated with 2% Triton X-100 or medium
alone, respectively. Cytolytic activity was calculated using the following
formula: percentage of specific Cr51 release = (experimental release −
spontaneous release) × 100 / (maximum release − spontaneous release).
Assays were performed in triplicate wells.
γ-Camera Imaging and Biodistribution Analysis
DCs were labeled with 111In oxinate (Nihon Medi-Physics, Hyogo,
Japan) in PBS for 20 minutes at room temperature. Cells were washed,
and the labeling efficiency was calculated as the percentage of activity
that remained associated with the cell pellet. For the in vivo studies,
five rats per experimental group were given intravenous injection of
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3 × 106 DCs (30 μCi) in 200 μl of PBS per rat. At different time
points, images were recorded with a CdTe semiconductor γ-camera
(MGC1500; Acrorad, Tokyo, Japan). For tissue biodistribution, groups
of five rats were analyzed 48 hours after injection of the 111In-labeled
DCs. Lungs, liver, kidneys, spleen, thymus, and lymph nodes (axillar,
hilar/mediastinal, abdominal, and pelvic/inguinal) were collected and
counted in the γ-counter. The measured activity in tissues and sam-
ples was expressed as a percentage of total detected dose.
Statistical Analysis
All data were expressed as means ± SD and were evaluated statis-
tically by repeated-measures one-way analysis of variance. The statis-
tical difference among groups was determined using Scheffé test, and
P < .05 was considered statistically significant.
Results
Characterization of rSeV/dF–Treated DCs Derived from Rat
Bone Marrow
At the initial stage of this study, we characterized rBM-DCs treated
with rSeV/dF, because this was the first time for us to examine the rat
DCs (Figure W1).
Two days after rSeV/dF-GFP exposure to a possible iDC-rich pop-
ulation (>95% of OX42+ in triplicate experiments) at an MOI of 30,
microscopic examination occasionally demonstrated large GFP-positive
cells showing typical dendrites. FACS analysis exhibited an apparent
dose-dependent increase in the GFP-positive cell ratio, up to approx-
imately 80%, without an apparent cytopathic effect as assessed by
7-amino-actinommycin D (7AAD) assay.
Next, we assessed whether rSeV/dF-GFP treatment led rBM-DCs
to an activated and mature state, as was demonstrated with murine
BM-DCs (mBM-DCs) in our previous study [10,11]. Similar to the
case of the mBM-DCs, nontransmissible rSeV/dF-GFP upregulated
CD80/B7-1 and CD86/B7-2 of rBM-DCs, findings that were not
apparent for CD40 and OX17 (MHC class II). Interestingly, the
expression level of the αE2 subunit of integrin on rat DCs, which
was recognized by mAb OX62, was more pronounced on rSeV/dF-
GFP-DCs than on LPS-activated DCs (LPS-DCs; data not shown;
representative data are demonstrated in Figure 4D). Proinflammatory
cytokines, including IL-1β, IL-6, and TNF-α, were also upregulated
by rSeV/dF-GFP treatment. However, the level did not reach those
observed by LPS treatment (data not shown; representative data are dem-
onstrated in Figure 4B). FITC-dextran uptake assay demonstrated time-
dependent impairment of endo-/phagocytotic activity of DCs treated
by LPS as well as rSeV/dF–null (for exclusion of GFP background),
Figure 1. Optimization of tumor lysate–pulsed rSeV/dF-GFP-DC vaccine on rat model of lung metastasis of AT6.3 prostate cancer. *P <
.01. (A) Treatment regimen. (B) Optimization of dose-efficacy relationship. DCs were administered through the tail vein. The following
numbers of animals were used: normal lung, n = 6; No Tx, n = 6; and rSeV/dF, n = 17 (3 × 104 cells, n = 6; 3 × 105 cells, n = 5; and
3 × 106 cells, n = 6). (C) Optimization of administration route. A total of 3 × 106 DCs were used per vaccine. The following numbers of
animals were used: normal lung, n = 6; No Tx, n = 9; and rSeV/dF, n = 16 (subcutaneous [s.c.] n = 7 and intravenous [i.v.] n = 9). (D)
Requirement of ex vivo pulsation of tumor lysate. A total of 3 × 106 DCs were used per vaccine. The following numbers of animals were
used: normal lung, n = 6; No Tx, n = 7; and rSeV/dF, n = 16 (−lysate n = 8 and +lysate n = 8). N.S. indicates not significant.
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whereas no significant reduction was observed in the case of iDCs, a
finding that conflicts with our previous data in use of mBM-DCs [11],
probably because of the species’ specificity. Furthermore, an allogeneic
mixed lymphocyte reaction assay revealed that both DC-activated LPS
and rSeV/dF-GFP could stimulate allogeneic T-cell proliferation.
These results indicate that, largely similar to the findings obtained
by the use of mBM-DCs [10,11], transfection of rSeV/dF could lead
to an activated and mature state of rBM-DCs.
Optimization of rSeV/dF-GFP-DC Vaccination in
Experimental Lung Metastasis of AT6.3
Next, we optimized rSeV/dF–based DC vaccination with tumor
lysate pulsation according to the number of DCs and route of adminis-
tration. The treatment regimen was demonstrated in Figure 1A. Ap-
parent and statistically significant reductions in wet lung weight and
the number of metastatic nodules were observed in a dose-dependent
manner; the optimized effect was observed at 3 × 106 cells of rSeV/
dF-GFP-DCs by intravenous vaccination through the tail vein (Fig-
ure 1B). The effect was markedly diminished when such DCs were
administered subcutaneously (Figure 1C ); therefore, all subsequent
experiments were done by intravenous administration of 3 × 106 cells
of DCs. We additionally examined whether ex vivo pulsation of tumor
lysate was required. As shown in Figure 1D, rSeV/dF-GFP-DCs con-
stantly showed an antimetastatic effect on AT6.3 irrespective of tumor
lysate pulsation.
Direct Comparison of Antimetastasis Efficacies
Next, we directly compared the antimetastatic effect of DCs (iDC,
LPS-DC, and rSeV/dF-GFP-DC) by the same treatment regimen
demonstrated in Figure 1A. We here included another iDC group,
iDC without tumor lysate, to exclude spontaneous activation of
DCs because of endo-/phagocytosis of the tumor antigen.
As shown in Figure 2, A to C , experimental lung metastasis was sig-
nificantly prevented in groups of LPS-DCs as well as in rSeV/dF-GFP-
DCs but not in any iDCs, and the finding was highly pronounced in
the use of rSeV/dF-GFP-DCs. A similar effect was observed in the use
of rSeV/dF-DCs without exogenous gene (data not shown). It was of
interest that CTL activity in splenocytes assessed at 3 weeks after tumor
inoculation showed no difference among the groups, indicating that
systemic tumor-specific CTL responses, at least, could be effectively
induced by intravenous administration of any types of DCs.
Figure 2. Direct comparison of antimetastatic ability of iDC, LPS-DC, and rSeV/dF-GFP-DC on rat model of lung metastasis of AT6.3
prostate cancer. (A-C) Direct comparison of efficacy of iDC with or without tumor lysate pulsation (n = 10, respectively), LPS-DC with
lysate (n = 11), and rSeV/dF-GFP-DC with lysate (n = 11): total wet lung weight (g) (A), number of metastatic nodules (B), and gross
observation of left upper lobe (C). Normal lung, n = 6; and No Tx, n = 11. The treatment regimen was the same as that in panel A. All
DCs were administered intravenously through the tail vein at 3 × 106 cells per vaccine. Note that the iDC group was included so as to
exclude the effect of spontaneous activation through tumor antigen capture. *P < .01 and #P < .05. (D) CTL activity assessed in use of
splenocytes. Each group contained n = 3.
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Therefore, these results suggest that other factors might contribute
to the strong antimetastatic ability of rSeV/dF-GFP-DCs.
In Vivo Trafficking of DCs
To explain the highly antimetastatic activity of rSeV/dF-GFP-DCs,
we first hypothesized that these DCs might be retained in the lung,
resulting in more pronounced antitumor responses at local sites. To
examine this possibility, we assessed the time course of in vivo traffick-
ing of DCs that were labeled by 111In oxinate.
Unexpectedly, the results were negative. At 3 hours after DC ad-
ministration, γ-camera imaging analysis revealed that most radio-
activities were distributed at the chest and, 21 hours later, at the
upper abdomen, irrespective of DC type (data not shown). To assess
this more precisely, these animals were killed, and the lysate of each
organ was subjected to the γ-counter 48 hours after DC administra-
tion (Figure 3A). Most radioactivities were accumulated in the liver,
and 15% to 20% was observed in the lung with the use of any DCs.
No significant differences were found in other lymphatic organs.
Subsequently, we also examined the expression of theDC-trafficking–
related molecules, including ICAM-1/CD54 and chemokine receptor
CCR7. Real-time PCR analyses revealed that messenger RNA expres-
sion of ICAM-1/CD54 and CCR7 was stimulated by LPS but not
by rSeV (Figure 3B); these findings differed from those observed in
DC surface expression of murine DCs [10].
These results suggested that the expression of some DC trafficking–
related molecules, ICAM-1/CD54 and CCR7, as well as the actual
trafficking of DCs in vivo were not likely to be important in the dif-
ferences in the antimetastatic activities among types of DCs in the rat
model of AT6.3 lung metastasis.
Effect of Dominant-Negative Mutant of RIG-I, RIG-IC,
on the Expression of IFN-β and Proinflammatory Cytokines
in rBM-DCs
Next, we hypothesized that the unique feature of rSeV, a negative-
strand RNA vector that replicates in the cellular cytoplasm [12–14],
might explain the superior antitumor effect of rSeV/dF-GFP-DCs
compared with other DCs. Since important studies recently revealed
that an RNA helicase, RIG-I, was critical for recognition of the RNA
genome of SeV for inducing various cellular responses, including ex-
pression of type I IFNs [16,17], we constructed a new rSeV/dF ex-
pressing a dominant-negative mutant of RIG-I, namely RIG-IC
(rSeV/dF-RIGIC) [21], to knock down the RIG-I–related signaling
in rSeV/dF–activated DCs.
As expected, rSeV/dF-GFP but not LPS selectively induced IFN-β
messenger RNA expression of rBM-DCs, an effect that was almost
completely diminished in DCs transfected by rSeV/dF-RIGIC (Fig-
ure 4A, right graph). In contrast, neither rSeV/dF-GFP nor LPS affected
the gene expression of IFN-α in DCs (Figure 4A, left graph). Interest-
ingly, the expression of RIG-IC almost completely diminished rSeV/
dF–related up-regulation of IL-1β, IL-6, and IL-12/p35 gene expres-
sion, too (Figure 4B). Because the enhancement of TNF-α protein se-
cretion and IL-12/p40 gene expression through rSeV/dF was modest,
the effect of RIG-IC expression on these was minimal. These results
indicated that RIG-I–related signaling induced by rSeV/dF was critical
not only for the expression of IFN-β but also for some typical pro-
inflammatory cytokines on rBM-DCs. We confirmed these findings
also in human peripheral blood–derived DCs and murine BM-DCs
(unpublished data).
DC surface markers, however, showed opposite results.
As shown in Figure 4C , upregulated expression of CD80/B7-1
and CD80/B7-2 on DCs through rSeV/dF was not affected by the
expression of RIG-IC. The expression of αE2-integrin on rBM-DCs,
which mAb OX62 recognized as an important marker of rat DCs,
was much accelerated by rSeV/dF-GFP compared with LPS. Impor-
tantly, rSeV/dF–mediated up-regulation of αE2-integrin was not sig-
nificantly affected by the expression of RIG-IC at all (Figure 4D).
These results strongly suggested that RIG-I–related signaling was
critical for inducing IFN-β and some proinflammatory cytokines on
DCs. However, the RNA genome of rSeV/dF might possibly be rec-
ognized by an RIG-I–independent mechanism that might contribute
to the expression of some surface markers, including CD80/B7-1 and
CD86/B7-2, as well as αE2-integrin.
RIG-IC Does Not Impair Antimetastatic Activity
of rSeV/dF-DCs
As a final assessment, we tested the antimetastatic activity of the vac-
cination of rSeV/dF-RIGIC-DCs on the AT6.3 experimental lung me-
tastasis model in the same regimen as that demonstrated in Figure 1A.
Figure 3. Trafficking of DCs in vivo. At 3 and 24 hours after intra-
venous administration of 3 × 106 111In oxinate-labeled DCs, the
whole body was screened by a γ-camera (data not shown). Twenty-
four hours later, the tissue samples were harvested and subjected
to a γ-counter. Each group contained n = 5. (A) Tissue distribution
of radioactivity 48 hours after DC administration. No difference in
accumulation was observed in any of the tissues sampled in this
study. (B) Gene expression of ICAM-1/CD54 and CCR7 in DCs after
treatment with LPS or rSeV/dF. Forty-eight hours after treatment,
total RNA was extracted and subjected to quantitative real-time
PCR. The GAPDH expression level was used for internal control of
relative expression, and the data were expressed as percentages
against relative expression of iDC.
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As shown in Figure 5, the expression of RIG-IC did not affect the
reduction of wet lung weight or the reduction in the number of meta-
static nodules at all. This indicated the essential contribution of RIG-
I–independent signaling on the antimetastatic ability of DCs activated
by rSeV/dF.
Discussion
We here investigated the potential of our recently developed DC-based
immunostimulatory virotherapy using nontransmissible rSeV/dF in an
immune-competent rat model of lung metastasis of highly malignant
prostate cancer AT6.3. The key observations obtained in this study
were as follows: 1) nontransmissible rSeV/dF transfected efficiently to
rBM-DCs without significant toxicity, and led them to the activation/
maturation state, findings that were representative of those observed
in murine DCs demonstrated in our previous study; 2) rSeV/dF–
modified DCs effectively prevented lung metastasis in a rat model of
prostate cancer; 3) the efficient antimetastatic activity of rSeV/dF-DCs
over iDCs and LPS-DCs was likely to depend on neither CTL activ-
ity nor DC trafficking; and 4) RIG-I–related signaling in rSeV/dF–
modified DCs was critical for cytokine production but not for their
antimetastatic activity.
Although there remain concerns regarding the molecular and im-
munologic mechanisms related to the antitumor activity of rSeV/dF-
DCs, this is the first report to indicate the high efficacy of prevention
for lung metastasis through vaccination of rSeV/dF–modified DCs.
Therefore, we believe that rSeV/dF–mediated immunostimulatory
virotherapy warrants further investigation as a new concept and a
promising tool for enhancing DC-mediated cancer immunotherapy.
The major concerns arising from the current study should focus
on the possible molecular mechanisms of rSeV/dF–related activation/
Figure 4. Type I IFN (A), typical proinflammatory cytokine (B), and surface marker (C and D) expression profiles in iDC, LPS-DC, rSeV/dF-
GFP-DC, and rSeV/dF-RIGIC-DC. Two days after treatment, gene or protein expression was determined by real-time quantitative RT-PCR
or ELISA (A or B) or by FACS analyses (C and D). *P < .01. (A) Gene expression of type I IFNs. rSeV/dF stimulated IFN-β but not IFN-α
expression, a finding diminished by rSeV/dF expressing RIG-IC, which is a dominant-negative inhibitor of a RNA helicase RIG-I. Each
group contained n = 4. (B) Protein secretion (ELISA: TNF-α) and gene expression (real-time quantitative RT-PCR: others). Note that rSeV/
dF–related up-regulation of IL-1β, IL-6, and IL-12/p35 was almost completely abolished by RIG-IC expression. Each group contained n =
3. (C and D) RIG-IC had no effect on surface markers of DCs, CD80/B7-1 and CD86/B7-2 (C), and αE2-integrin, a target antigen of OX62
(D). Each group contained n = 4 (C) and n = 12 (D, total of three independent experiments).
Figure 5. Antimetastatic activity of rSeV/dF–modified DC does not
depend on RIG-I–related signaling. Comparison of the efficacy of
rSeV/dF–modified DC expressing a reporter gene (GFP: n = 6) or
RIG-IC (n = 6); total wet lung weight (g) (left graph) and the num-
ber of metastatic nodules (right graph) were demonstrated. Nor-
mal lung, n = 6; and No Tx, n = 11. Treatment regimen was
followed as in Figure 1A. All DCs were administered intravenously
through the tail vein at 3 × 106 cells per vaccine. *P < .01.
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maturation of DCs. Of interest, we here demonstrated the divergent
expression patterns between cytokines and DC surface markers; the
former was RIG-I–dependent, and the latter, including the target of
OX62 αE2-integrin, was independent. According to recent extensive
studies done by Kawai et al. [16], Kato et al. [17], and Yoneyama
et al. [21], the RIG-I–dependent expressional regulation of proinflam-
matory cytokines, as well as that of IFN-β, has been expected in our
cases of rSeV/dF-DCs. Unexpectedly, however, the up-regulation of
DC surface proteins induced by rSeV/dF was independent of RIG-I–
related signaling in rat DCs. There are two possible explanations: 1)
the fusion of the envelope, but not of the genomic ribonucleotide
protein complex, of rSeV/dF stimulated the expression of surface pro-
teins; or 2) an alternative pathway that recognizes the replication/
transcription of the genome of rSeV/dF stimulated surface marker
expression but not proinflammatory cytokines. The former seems un-
likely because some studies from different laboratories demonstrated
that the use of the envelope of SeV did not evoke the up-regulation
of surface markers, thus suggesting DC activation/maturation [23–
25]. We also confirmed that UV-inactivated rSeVs stimulated neither
cytokines nor activation markers on DCs derived from human periph-
eral blood and murine bone marrow (data not shown). Furthermore,
rSeV/dF–mediated up-regulation of CD80/B7-1, CD86/B7-2, and
αE2-integrin was not a result of the autocrine effect of cytokines
because the expression of these markers was not protected by RIG-
IC expression. Therefore, it seems reasonable to hypothesize that the
cytoplasmic alternative molecules, but not RIG-I, may recognize the
RNA genome of rSeV/dF for inducing surface markers but not for in-
ducing cytokine expression. Further studies should be conducted to
clarify these questions.
The second question is which factor(s) and/or effector(s) deter-
mined the differences in antimetastatic activity among iDC, LPS-
DC, and rSeV/dF-DC. As the present study demonstrated, splenic
CTL activity as well as DC trafficking, at least, showed no apparent
differences among these groups. It is hard for us, at present, to sug-
gest a definitive answer because we have data indicating that direct
cytolytic activity [26] could not be detected in these DCs (data not
shown), and immunohistochemical studies have revealed the infiltra-
tion of similar numbers of CD4+ and CD8+ cells into the lung (data
not shown). Although a large part of the possible mechanisms may be
speculative, one possible explanation is the balance of expression be-
tween IL-12/p35 and IL-12/p40 in DCs. It has been well known
that IL-12p75 (or IL-12p70), commonly IL-12 heterodimerically
composed of a p35 subunit and a p40 subunit, is involved not only
in the induction but also in the maintenance of TH1 responses, as
well as in stimulating NK cell activity [27–29]. Both murine and hu-
man p40 homodimers, in contrast, are shown to act as antagonists of
IL-12 [29]. In the present study, we demonstrated that LPS strongly
stimulated both p35 and p40, whereas rSeV/dF-GFP selectively in-
duced p35 dominantly, and lesser extent to p40 (Figure 4B), suggest-
ing the more pronounced TH1 response and NK cell activity in DC
vaccination using rSeV/dF than that observed by LPS. Particularly,
NK cell activity seems possibly essential in the antimetastatic activity
of rSeV/dF-DCs expressing lower levels of p40 because it was shown
that IL-12p40 secretion suppressed NK cell activity, allowing the
growth of cancer cells in vivo [30]. Some studies, however, have
shown the divergent expression of p40 by SeV in human and murine
macrophage-lineage cells [31,32], conflicting with our current find-
ings obtained using rat BM-DCs. Therefore, because there are a num-
ber of limitations for us to assess regarding detailed immunologic
aspects of the rat model, further studies are required using murine
models of lung metastasis.
In this regard, we recently published an article demonstrating that
rSeV-DC–based efficient prevention of lung metastasis of RM-9 pros-
tate cancer was a NK/CD4+ cell–dependent mechanism [33]. Inter-
estingly, the antimetastatic effect was sustained during 3 months,
even when administered DCs were already cleared from the lung
and organs related to the immune system. Furthermore, although
NK cell activity had already declined to baseline at the time of tumor
inoculation, antibody-mediated depletion studies revealed that CD4+
cells as well as the presence of, but not activation of, NK cells were
crucial for prevention of lung metastasis. These results indicate that
the efficient inhibition of lung metastasis through bolus administra-
tion of virally activated DCs that was sustained and NK/CD4+ cell–
dependent, but not RIG-I–independent, suggesting a potentially new
mechanism of DC-based immunotherapy for advanced malignancies.
Although some concerns remain to be clarified, we believe that a lack
of information regarding some mechanistic aspects does not always di-
minish the value of rSeV-DC–based immunostimulatory virotherapy
because this system representatively showed strong antitumor effects
in some tumor models and species even when used for highly malig-
nant tumor models [10,11]. Because rSeV/dF is now available for
clinical study and because the preparation of rSeV/dF–modified DC
does not require any specific techniques or materials, we should in-
vestigate whether this system may show a significant antitumor effect
over the current cancer vaccines in clinical settings.
In conclusion, we here successfully demonstrated a highly efficient
antimetastatic activity of nontransmissible rSeV-modified DC in a rat
model of prostate cancer. These results prompt us to make further
investigations toward clinical applications.
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Supplementary Methods
Transfection Efficiency and Cytopathic Effect on rBM-DCs
The transfection efficiency of SeV/dF-GFP in rBM-DCs was eval-
uated. On day 7, immature rBM-DCs propagated in the presence of
GM-CSF and IL-4 were collected. rBM-DCs were transfected with
SeV/dF-GFP at MOI 1 to 300. Forty-eight hours after SeV/dF infec-
tion, rBM-DCs were analyzed by flow cytometry for GFP expression.
Cell viability was also assessed with 7AAD to count living cells, as
previously described [1].
FITC-Dextran Uptake
FITC-dextran uptake assay was performed to assess the endo-/
phagocytotic activity of DCs. DCs were plated in fresh medium (1 ×
106 cells/ml) and were incubated with or without rSeV/dF-GFP or
LPS (1 ng/ml), and DCs were harvested at different times after stimu-
lation. Acquired DCs were suspended in RPMI 1640 with 10% fetal
calf serum and incubated with 1 mg/ml of FITC-dextran (MWt =
40,000; Sigma-Aldrich) for 30 minutes at 4 or 37°C. Cells were washed
three times with ice-cold PBS, and mean fluorescent intensity of FITC
was analyzed by FACScalibur (BD Biosciences, Franklin Lakes, NJ).
The uptake was calculated as the change in mean fluorescent intensity
between cell samples incubated at 37°C and 4°C.
Allogeneic Mixed Lymphocyte Reactions
Allogeneic mixed lymphocyte reactions were performed to assess the
antigen-presenting ability of DCs. Total splenocytes were obtained
from allogeneic Wistar rats. Red blood cells were lysed using VersaLyse
Lysing solution and served as responder cells. In vitro–generated imma-
ture rBM-DCs, as well as rSeV/dF-GFP-DCs and LPS-DCs stimu-
lated on day 7, were collected at day 9. These DCs were irradiated
with 3000 rad and then used as stimulator cells. Total splenocytes
freshly extracted from Copenhagen rats were also irradiated and used
as control stimulator APC. Allogeneic responder cells (1 × 105 cells/
wells) were cultured in triplicate in a 96-well round-bottom microplate
with different numbers of stimulator APCs (APC–to–T-cell ratios
were 1:1, 1:10, and 1:100). Cultures were maintained in a humidified
atmosphere at 37°C and 5% CO2. The thymidine analog bromode-
oxyuridine (BrdU) was added on day 3 followed by quantitation of
incorporated BrdU after a further 16 hours of culture using an ELISA-
based cell proliferation kit (BrdU colorimetric, 1647229; Roche,
Mannheim, Germany) according to the manufacturer’s protocol.
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Table W1. Primers Used for Real-time PCR Analysis.
Rat IFN-α: amplicon size = 130 bp
Forward: 5′-CCTGCCTCATACTCATAACC-3′
Reverse: 5′-GCCATCCACCTTCTCCAA-3′
Rat IFN-β: amplicon size = 84 bp
Forward: 5′-CTTTGCCATTCAAGTGATGCTC-3′
Reverse: 5′-ACAATAGTCTCATTCCACCAGTG-3′
Rat IL-1β: amplicon size = 235 bp
Forward: 5′-ATGGTCGGGACATAGT-3′
Reverse: 5′-GTGGTTGCCTGTCAGA-3′
Rat IL-12 p35 subunit: amplicon size = 235 bp
Forward: 5′-GACTTGAAGATGTACCAGTCA-3′
Reverse: 5′-GCATTAGCTCATCAATAGCC-3′
Rat IL-12 p40 subunit : amplicon size = 210 bp
Forward: 5′-TCATCAGGGACATCATCAAACC-3′
Reverse: 5′-CGAGGAACGCACCTTTCTG-3′
Rat IL-6: amplicon size = 151 bp
Forward: 5′-CAAAGCCAGAGTCCATTCAGAGC-3′
Reverse: 5′-GGTCCTTAGCCACTCCTTCTGT-3′
Rat ICAM-1/CD54: amplicon size = 71 bp
Forward: 5′-AAACGGGAGATGAATGGTACCTAC-3′
Reverse: 5′-TGCACGTCCCTGGTGATACTC-3′
Rat CCR7: amplicon size = 307 bp
Forward: 5′-TGGTTATCATCCGCACTCTG-3′
Reverse: 5′-CAGCCCAAGTCCTTGAAGAG-3′
GAPDH: amplicon size = 177 bp
Forward: 5′-TGCACCACCAACTGCTTAG-3′
Reverse: 5′-GGATGCAGGGATGATGTTC-3′
Figure W1. Characterization of rBM-DCs transfected by nontransmissible rSeV/dF-GFP ex vivo. Seven days after cultivation under the
presence of rat IL-4 and GM-CSF for differentiating iDCs, fresh medium with rSeV/dF-GFP was added, and cells were examined for the
following examinations. Panels A to D were done more than three times each, showing similar results. (A) Spontaneous maturation of
rBM-DCs by transfection of rSeV/dF-GFP. Two days after transfection, cells were examined under a fluorescent microscope. Larger cells
showing dendrites positive for GFP were demonstrated. (B and C) Dose-dependent transfection efficiency (B, %GFP-positive cells) and
cytopathic effect (C, %cell viability assessed by 7AAD assay). Approximately 80% of iDCs could be transfected by rSeV/dF-GFP, show-
ing no apparent cytopathic effect under MOI = 0 to 300. (D) Spontaneous up-regulation of typical surface markers (CD80/B7-1 and
CD86/B7-2) 2 days after transfection of rSeV/dF-GFP (MOI = 100). LPS (1 μg/ml) was used for a positive control. Both CD80/B7-1
and CD86/B7-2 were upregulated by rSeV/dF-GFP treatment, whereas the expression of neither CD40 nor OX17 was significantly en-
hanced by rSeV/dF-GFP, findings that were similar to those observed in murine DCs treated with replication-competent rSeV in our
previous study [2,3]. (E) Time course of FITC-dextran uptake of iDCs, LPS-DCs, and rSeV/dF–null-DCs to assess endo-/phagocytotic
activity of DCs. Note the use of rSeV/dF–null instead of rSeV/dF-GFP to avoid background fluorescence. Each group contained n =
3. rSeV/dF treatment caused the loss of the endo-/phagocytotic activity of rBM-DCs, a conflicting result that was observed in case
of murine BM-DCs [3], probably because of the species’ specificity. (F) Allostimulatory activity of DCs. Allogeneic T cells were cultured
with each DC for 48 hours, at which point allostimulation was determined by proliferation as described in Materials and Methods. No
significant difference was observed among iDC, LPS-DC, and rSeV/dF-GFP-DC. Each group contained n = 3. Allo-MLR indicates allo-
geneic mixed lymphocyte reaction.
